Search
for
Sort by
Research 151–180 of 1000+
- Número Actual: Vol. 2 Núm. 4 (2021) Pág. 1-67
- The clinical course and outcomes of SARS-CoV-2 virus infection in children: a 24-week follow-up study in Sulaimaniyah, Iraq
- 28th Turkish National Dermatology Congress, September 24–28, 2019, Antalya, Turkey
- Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24‐week randomized, double‐blind, placebo‐controlled clinical trial
- Trichoscopic Markers and Clinical Response Patterns With Ritlecitinib in Severe Alopecia Areata: 24‐Week Outcomes From a Prospective Real‐World Cohort
- Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study
- Faculty Opinions recommendation of Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial.
- Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indol-5(2<i>H</i>)-yl)acetic Acid (Setipiprant/ACT-129968)
- Hair Growth-Promoting Effects of a Multi-Targeted Cosmetic Formulation Containing PYGL, DP2, and 15-PGDH Inhibitors Developed Using AI-Based DeepZema® in Androgenetic Alopecia: A 24-Week Randomized Controlled Trial
- 1. 2年間の低負荷レジスタンストレーニングが高齢者の筋機能に及ぼす効果(第134回日本体力医学会関東地方会)
- Discovery of (2<i>S</i>)-<i>N</i>-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- A Novel Approach Against Male Pattern Hair Loss With Topical Dimethylglycine Sodium Salt (DMG‐Na) and Caffeine: Efficacy of a 24‐Week, Double‐Blind, Randomized, Placebo‐Controlled Trial
- Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- BindingDB Entry 50021519: Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment.
- 61720 The effect of sublingual minoxidil on androgenetic alopecia in transgender individuals receiving testosterone for gender-affirmation: A 24-week single-centre double-blinded, randomized, placebo-controlled clinical trial
- Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Abstracts of the 28th Annual Congress of the ECVD‐ESVD, 24–26 September 2015, Krakow, Poland
- Highlights from the Basics in Hair Restoration Course Afternoon Hands-On Stations Wednesday, August 24, 2005
- European Society of Hair Restoration Surgery: 10th Annual Congress & Live Surgery Workshop, Paris, France • May 24–27, 2007
- 15<sup>th</sup>Jornada de DermatologÃa of the Faculty of Medicine, ClÃnica Alemana â University of Desarrollo, Santiago, Chile, October 22-24, 2009
- Electron microscopy in dermatology--basic and clinical research : proceedings of the Joint Meeting for the Japanese Society for Ultrastructural Cutaneous Biology and the Society for Cutaneous Ultrastructure Research, Nara, Japan, 24-27 October 1993
- Type 2 Cytokine–Dependent Skin Barrier Regulation in Personalized 2-Dimensional and 3-Dimensional Skin Models of Atopic Dermatitis: A Pilot Study
- 1617 Impact of type 2 cytokines on the keratinocytes-s. aureus interaction
- 139 Anti-BCC efficacy of a topical hedgehog inhibitor without adverse effects in BCNS patients in a phase 2 randomized controlled trial
- Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
- Role of thymosin beta 4 in hair growth
- 219 Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid